文献速递烧伤创面修复

烧伤与肾脏清除率增强:一例哌拉西林-他唑巴坦剂量优化的病例分析

Burn Injury and Augmented Renal Clearance: A Case for Optimized Piperacillin-Tazobactam Dosing.
PubMed 文献 · J Burn Care Res · 2023-01-01

本病例报告描述一名肥胖患者,3.2%体表面积部分厚度烧伤后并发铜绿假单胞菌烧伤创面蜂窝织炎,测得肌酐清除率证实存在肾脏清除率增强(ARC),启动哌拉西林-他唑巴坦每日22.5克持续输注,稳态哌拉西林治疗药物监测浓度为78 mcg/mL,达到预设目标。作者建议识别ARC时使用哌拉西林-他唑巴坦持续输注,并呼吁进一步前瞻性研究。

要点

  • 烧伤患者感染风险高且抗菌药物药代动力学可能改变。
  • 本病例中肥胖患者3.2%体表面积烧伤并发铜绿假单胞菌蜂窝织炎,测得ARC。
  • 作者建议识别ARC时使用哌拉西林-他唑巴坦持续输注。

核心结论

  • 作者建议当识别出肾脏清除率增强(ARC)时,使用哌拉西林-他唑巴坦持续输注。
  • 作者认为需要进一步前瞻性研究来分类烧伤合并ARC患者的发生率、危险因素和适宜抗菌方案。

研究设计与样本

  • 病例报告:一名肥胖患者,3.2%体表面积部分厚度烧伤,并发铜绿假单胞菌烧伤创面蜂窝织炎。

主要发现

  • 测得肌酐清除率记录到肾脏清除率增强(ARC)的存在。
  • 启动哌拉西林-他唑巴坦每日22.5克持续输注。
  • 稳态时哌拉西林治疗药物监测浓度为78 mcg/mL,达到预设目标哌拉西林浓度(假设铜绿假单胞菌对哌拉西林-他唑巴坦敏感的最低抑菌浓度为16/4 mcg/mL时,100% 4倍最低抑菌浓度)。
  • 现有文献提示,较年轻的危重症患者且器官衰竭评分较低者,以及烧伤面积体表面积百分比较高的烧伤患者,最可能表现出ARC,这与本患者的特征不完全一致。
  • 哌拉西林-他唑巴坦在ARC、烧伤和肥胖人群中与药代动力学改变相关,标准剂量未能达到目标 attainment。

关键数值与推荐

  • 预设目标哌拉西林浓度为100% 4倍最低抑菌浓度,假设铜绿假单胞菌对哌拉西林-他唑巴坦敏感的最低抑菌浓度为16/4 mcg/mL(根据临床和实验室标准协会)。
  • 稳态哌拉西林治疗药物监测浓度为78 mcg/mL。
  • 哌拉西林-他唑巴坦剂量为每日22.5克持续输注。

临床怎么用

  • 作者建议当识别出肾脏清除率增强(ARC)时,使用哌拉西林-他唑巴坦持续输注。
  • 本病例报告描述了非危重症烧伤患者中ARC的独特发现,并论证了进一步前瞻性研究的必要性。

局限性

  • 本病例报告描述了非危重症烧伤患者中ARC的独特发现,并论证了需要进一步前瞻性研究来分类发生率、危险因素和适宜抗菌方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with burn injuries are at high risk for infection as well as altered antimicrobial pharmacokinetics. Patients suffering from a burn injury, generally encompassing a total body surface area (TBSA) ≥ 20%, have been cited as at risk for augmented renal clearance (ARC). Our case report describes an obese patient with 3.2% TBSA partial thickness burns who suffered from burn wound cellulitis with Pseudomonas aeruginosa. Measured CLcr documented the presence of ARC, and 22.5 grams daily continuous infusion of piperacillin-tazobactam was initiated. Therapeutic monitoring of piperacillin at steady state was 78 mcg/mL, achieving the prespecified goal piperacillin concentration of 100% 4-times the minimum inhibitory concentration assuming MIC for susceptible P. aeruginosa at 16/4 mcg/mL per Clinical Laboratory Standards Institute. Available literature suggests younger critically ill patients with lower organ failure scores, and for a burn injury, a higher percentage of TBSA, are most likely to exhibit ARC which does not entirely align with the characteristics of our patient. In addition, piperacillin-tazobactam has been associated with altered pharmacokinetics in ARC, burn, and obese populations, demonstrating failure to meet target attainment with standard doses. We suggest a continuous infusion of piperacillin-tazobactam be used when ARC is identified. This case report describes the unique findings of ARC in a non-critically ill burn patient and rationalizes the need for further prospective research to classify incidence, risk factors, and appropriate antimicrobial regimens for burn patients with ARC.

来源:J Burn Care Res,查看原文。版权归原作者所有。

引用

  1. Torian SC, Wiktor AJ, Roper SE, et al. Burn Injury and Augmented Renal Clearance: A Case for Optimized Piperacillin-Tazobactam Dosing. J Burn Care Res. 2023. PMID: 36173707. doi:10.1093/jbcr/irac138

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。